array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(26) "Bio-RAD Laboratories, Inc."
["slug"]=>
string(33) "001cd-us-bio-rad-laboratories-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/9d1c28c2-1b47-4093-8ed2-5151f3fe7920"
["description"]=>
string(867) "Since Bio-Rad was founded 70 years ago, we have continued to provide the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process and medical diagnostic labs obtain faster, better results. Throughout our existence, we have built long-lasting customer relationships that help advance our research and development efforts in the introduction of new products and solutions. Today, Bio-Rad is a global leader, with a team of over 8,000 employees and a global network of operations that serves our life science research and clinical diagnostics customers, advancing science and saving lives, together.
#Biotechnology #Biotech #STEM #Research #Biology #Chemistry #Science #PeerReviewed #Diabetes #CancerResearch #HIVResearch #Laboratory #BioRad #Cancer #DiabetesResearch #AIDSResearch #ClinicalDiagnostics"
["address_street"]=>
string(20) "1000 Alfred Nobel Dr"
["address_place"]=>
string(8) "Hercules"
["address_region"]=>
string(10) "California"
["founding_date"]=>
string(10) "1952-02-08"
["website_domain"]=>
string(11) "bio-rad.com"
["website_url"]=>
string(23) "https://www.bio-rad.com"
["industry_codes"]=>
array(3) {
[0]=>
string(42) "In Vitro and In Vivo Diagnostic Substances"
[1]=>
string(33) "Laboratory Analytical Instruments"
[2]=>
string(47) "Electromedical and Electrotherapeutic Apparatus"
}
["employee_count"]=>
int(7900)
["article_count"]=>
int(661)
}
["articles"]=>
array(7) {
[0]=>
array(7) {
["title_en"]=>
string(75) "Bio-Rad and QIAGEN announce patent settlement and cross-licensing agreement"
["snippet_en"]=>
string(300) "Hercules, Calif., and Venlo, the Netherlands, July 26, 2023( GLOBE NEWSWIRE) -- Bio-Rad Laboratories, Inc.( NYSE: BIO and BIOb) and QIAGEN N.V.( NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court"
["url"]=>
string(76) "https://finance.yahoo.com/news/bio-rad-qiagen-announce-patent-201500562.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/3d3721dc-43e4-4795-87db-f774b7c41b35"
["source"]=>
string(9) "yahoo.com"
["publication_date"]=>
string(10) "2023-07-26"
["categories"]=>
array(5) {
[0]=>
string(16) "Case Settlements"
[1]=>
string(46) "Management of Legal and Regulatory Environment"
[2]=>
string(5) "Legal"
[3]=>
string(27) "Business Model & Innovation"
[4]=>
string(21) "Intellectual Property"
}
}
[1]=>
array(7) {
["title_en"]=>
string(75) "Bio-Rad and QIAGEN announce patent settlement and cross-licensing agreement"
["snippet_en"]=>
string(197) "Hercules, Calif., and Venlo, the Netherlands, July 26, 2023 (GLOBE NEWSWIRE) — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today..."
["url"]=>
string(165) "https://portal.sina.com.hk/finance/finance-globenewswire/globenewswire/2023/07/26/439908/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/5754d4ca-b8d3-4c18-a04d-7b4502c29676"
["source"]=>
string(11) "sina.com.hk"
["publication_date"]=>
string(10) "2023-07-26"
["categories"]=>
array(4) {
[0]=>
string(27) "Business Model & Innovation"
[1]=>
string(13) "Collaboration"
[2]=>
string(16) "Case Settlements"
[3]=>
string(5) "Legal"
}
}
[2]=>
array(7) {
["title_en"]=>
string(64) "Qiagen Sues Bio-Rad to Stave Off Patent Suit on DNA-Tagging Tech"
["snippet_en"]=>
string(254) "Qiagen NV filed a lawsuit Wednesday against Bio-Rad Laboratories Inc. seeking a federal court’ s judgment that Qiagen’ s QIAcuity system, which it says has been used in 48 states to test municipal wastewater for signs of Covid-19, doesn’ t infringe"
["url"]=>
string(101) "https://news.bloomberglaw.com/ip-law/qiagen-sues-bio-rad-to-stave-off-patent-suit-on-dna-tagging-tech"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/54380145-4298-49d2-9f3c-69c88b11fc5e"
["source"]=>
string(16) "bloomberglaw.com"
["publication_date"]=>
string(10) "2022-04-06"
["categories"]=>
array(7) {
[0]=>
string(46) "Management of Legal and Regulatory Environment"
[1]=>
string(5) "Legal"
[2]=>
string(27) "Business Model & Innovation"
[3]=>
string(8) "Verdicts"
[4]=>
string(8) "Epidemic"
[5]=>
string(21) "Intellectual Property"
[6]=>
string(10) "Litigation"
}
}
[3]=>
array(7) {
["title_en"]=>
string(71) "Bio-Rad, Harvard settle DNA analysis patent dispute with French company"
["snippet_en"]=>
string(206) "Bio-Rad Laboratories has settled its patent infringement claims against French biotech company Stilla Technologies three days after the start of a trial in Boston federal court, according to a court filing."
["url"]=>
string(126) "https://www.reuters.com/legal/transactional/bio-rad-harvard-settle-dna-analysis-patent-dispute-with-french-company-2021-07-08/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/3b60c69a-bc98-4e16-8fcd-86222fa59002"
["source"]=>
string(11) "reuters.com"
["publication_date"]=>
string(10) "2021-07-08"
["categories"]=>
array(9) {
[0]=>
string(17) "Business Disputes"
[1]=>
string(16) "Case Settlements"
[2]=>
string(46) "Management of Legal and Regulatory Environment"
[3]=>
string(5) "Legal"
[4]=>
string(27) "Business Model & Innovation"
[5]=>
string(8) "Verdicts"
[6]=>
string(21) "Competitive Behaviour"
[7]=>
string(21) "Intellectual Property"
[8]=>
string(10) "Litigation"
}
}
[4]=>
array(7) {
["title_en"]=>
string(61) "Single-Cell Sequencing: Paving the Way for Precision Medicine"
["snippet_en"]=>
string(119) "Single-cell sequencing is the next step in innovation towards making precision medicine more accurate than ever before."
["url"]=>
string(57) "https://www.labiotech.eu/in-depth/single-cell-sequencing/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/fd43e7e3-1321-482e-aa27-432ce88e3ffd"
["source"]=>
string(12) "labiotech.eu"
["publication_date"]=>
string(10) "2021-01-27"
["categories"]=>
array(1) {
[0]=>
string(27) "Business Model & Innovation"
}
}
[5]=>
array(7) {
["title_en"]=>
string(75) "Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement"
["snippet_en"]=>
string(292) "Bio-Rad Laboratories, Inc.( NYSE: BIO and BIOb) and QIAGEN N.V.( NYSE: QGEN; Frankfurt Prime Standard: QIA), today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing"
["url"]=>
string(137) "https://www.morningstar.com/news/business-wire/20230726552882/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement"
["image_url"]=>
NULL
["source"]=>
string(15) "morningstar.com"
["publication_date"]=>
NULL
["categories"]=>
array(5) {
[0]=>
string(13) "Collaboration"
[1]=>
string(16) "Case Settlements"
[2]=>
string(5) "Legal"
[3]=>
string(27) "Business Model & Innovation"
[4]=>
string(15) "Deals & Tenders"
}
}
[6]=>
array(7) {
["title_en"]=>
string(50) "Qiagen: Good business even without the Corona hype"
["snippet_en"]=>
string(239) "02/06/2023 - Acquisitions are part of Qiagen's business model. The specialist in diagnostics has just announced the takeover of its American cooperation partner Verogen for 150 million dollars. The acquisition has specialized in forensics."
["url"]=>
string(94) "https://www.wallstreet-online.de/nachricht/16522246-egbert-prior-qiagen-geschaefte-corona-hype"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/c65fbbf0-ce0b-4428-b5ae-7eaf352ca9bc"
["source"]=>
string(20) "wallstreet-online.de"
["publication_date"]=>
NULL
["categories"]=>
array(5) {
[0]=>
string(27) "Business Model & Innovation"
[1]=>
string(6) "Merger"
[2]=>
string(8) "Epidemic"
[3]=>
string(11) "Acquisition"
[4]=>
string(25) "Business Model Resilience"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(66)
}
[1]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(51)
}
[2]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(31)
}
[3]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(28)
}
[4]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(26)
}
[5]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(24)
}
[6]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(23)
}
[7]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(20)
}
[8]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(19)
}
[9]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(19)
}
[10]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(19)
}
[11]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(18)
}
[12]=>
array(2) {
["name"]=>
string(14) "Issuing Shares"
["count"]=>
int(14)
}
[13]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(14)
}
[14]=>
array(2) {
["name"]=>
string(18) "Ecological Impacts"
["count"]=>
int(13)
}
[15]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(13)
}
[16]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(9)
}
[17]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(9)
}
[18]=>
array(2) {
["name"]=>
string(10) "New Market"
["count"]=>
int(9)
}
[19]=>
array(2) {
["name"]=>
string(11) "Regulations"
["count"]=>
int(9)
}
[20]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(8)
}
[21]=>
array(2) {
["name"]=>
string(11) "Competition"
["count"]=>
int(7)
}
[22]=>
array(2) {
["name"]=>
string(27) "Business Model & Innovation"
["count"]=>
int(7)
}
[23]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(7)
}
[24]=>
array(2) {
["name"]=>
string(6) "Merger"
["count"]=>
int(7)
}
[25]=>
array(2) {
["name"]=>
string(16) "Case Settlements"
["count"]=>
int(6)
}
[26]=>
array(2) {
["name"]=>
string(13) "Credit Rating"
["count"]=>
int(5)
}
[27]=>
array(2) {
["name"]=>
string(15) "Business Ethics"
["count"]=>
int(5)
}
[28]=>
array(2) {
["name"]=>
string(25) "Business Model Resilience"
["count"]=>
int(5)
}
[29]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(5)
}
}
}
001cd-us-bio-rad-laboratories-inc
Bio-RAD Laboratories, Inc.
Location
California
Founded
1952-02-08
Website
https://www.bio-rad.com
Articles
661 Articles
Category
In Vitro and In Vivo Diagnostic Substances
Laboratory Analytical Instruments
Electromedical and Electrotherapeutic Apparatus
Description
Since Bio-Rad was founded 70 years ago, we have continued to provide the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process and medical diagnostic labs obtain faster, better results. Throughout our existence, we have built long-lasting customer relationships that help advance our research and development efforts in the introduction of new products and solutions. Today, Bio-Rad is a global leader, with a team of over 8,000 employees and a global network of operations that serves our life science research and clinical diagnostics customers, advancing science and saving lives, together.
#Biotechnology #Biotech #STEM #Research #Biology #Chemistry #Science #PeerReviewed #Diabetes #CancerResearch #HIVResearch #Laboratory #BioRad #Cancer #DiabetesResearch #AIDSResearch #ClinicalDiagnostics
Hercules, Calif., and Venlo, the Netherlands, July 26, 2023( GLOBE NEWSWIRE) -- Bio-Rad Laboratories, Inc.( NYSE: BIO and BIOb) and QIAGEN N.V.( NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court
Hercules, Calif., and Venlo, the Netherlands, July 26, 2023 (GLOBE NEWSWIRE) — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today...
Qiagen NV filed a lawsuit Wednesday against Bio-Rad Laboratories Inc. seeking a federal court’ s judgment that Qiagen’ s QIAcuity system, which it says has been used in 48 states to test municipal wastewater for signs of Covid-19, doesn’ t infringe
Bio-Rad Laboratories has settled its patent infringement claims against French biotech company Stilla Technologies three days after the start of a trial in Boston federal court, according to a court filing.
Bio-Rad Laboratories, Inc.( NYSE: BIO and BIOb) and QIAGEN N.V.( NYSE: QGEN; Frankfurt Prime Standard: QIA), today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing
02/06/2023 - Acquisitions are part of Qiagen's business model. The specialist in diagnostics has just announced the takeover of its American cooperation partner Verogen for 150 million dollars. The acquisition has specialized in forensics.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
